Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine

Nanxi Wang, Zhe Yuan, Wei Niu, Qingsheng Li, Jiantao Guo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

While the combined antiretroviral therapy has resulted in a significant decrease in HIV-1 related morbidity and mortality, the HIV-1 pandemic has not been substantially averted. To curtail the 2.4 million new infections each year, a prophylactic HIV-1 vaccine is urgently needed. This review first summarizes four major completed clinical efficacy trials of prophylactic HIV-1 vaccine and their outcomes. Next, it discusses several other approaches that have not yet advanced to clinical efficacy trials, but provided valuable insights into vaccine design. Among them, live-attenuated vaccines (LAVs) provided excellent protection in a non-human primate model. However, safety concerns have precluded the current version of LAVs from clinical application. As the major component of this review, two synthetic biology approaches for improving the safety of HIV-1 LAVs through controlling HIV-1 replication are discussed. Particular focus is on a novel approach that uses unnatural amino acid-mediated suppression of amber nonsense codon to generate conditionally replicating HIV-1 variants. The objective is to attract more attention towards this promising research field and to provoke creative designs and innovative utilization of the two control strategies.

Original languageEnglish (US)
Pages (from-to)455-462
Number of pages8
JournalJournal of Chemical Technology and Biotechnology
Volume92
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Synthetic Biology
AIDS Vaccines
Attenuated Vaccines
Vaccines
vaccine
human immunodeficiency virus
HIV-1
Amber
Amino Acids
Clinical Trials
safety
Safety
amber
Nonsense Codon
Pandemics
morbidity
Amino acids
primate
Primates
amino acid

Keywords

  • HIV-1 vaccine
  • amber suppression
  • live-attenuated vaccine
  • unnatural amino acid
  • virus engineering

ASJC Scopus subject areas

  • Biotechnology
  • Chemical Engineering(all)
  • Renewable Energy, Sustainability and the Environment
  • Fuel Technology
  • Waste Management and Disposal
  • Pollution
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine. / Wang, Nanxi; Yuan, Zhe; Niu, Wei; Li, Qingsheng; Guo, Jiantao.

In: Journal of Chemical Technology and Biotechnology, Vol. 92, No. 3, 01.03.2017, p. 455-462.

Research output: Contribution to journalArticle

@article{90ff4363a6d34175bf08d43ab50ea587,
title = "Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine",
abstract = "While the combined antiretroviral therapy has resulted in a significant decrease in HIV-1 related morbidity and mortality, the HIV-1 pandemic has not been substantially averted. To curtail the 2.4 million new infections each year, a prophylactic HIV-1 vaccine is urgently needed. This review first summarizes four major completed clinical efficacy trials of prophylactic HIV-1 vaccine and their outcomes. Next, it discusses several other approaches that have not yet advanced to clinical efficacy trials, but provided valuable insights into vaccine design. Among them, live-attenuated vaccines (LAVs) provided excellent protection in a non-human primate model. However, safety concerns have precluded the current version of LAVs from clinical application. As the major component of this review, two synthetic biology approaches for improving the safety of HIV-1 LAVs through controlling HIV-1 replication are discussed. Particular focus is on a novel approach that uses unnatural amino acid-mediated suppression of amber nonsense codon to generate conditionally replicating HIV-1 variants. The objective is to attract more attention towards this promising research field and to provoke creative designs and innovative utilization of the two control strategies.",
keywords = "HIV-1 vaccine, amber suppression, live-attenuated vaccine, unnatural amino acid, virus engineering",
author = "Nanxi Wang and Zhe Yuan and Wei Niu and Qingsheng Li and Jiantao Guo",
year = "2017",
month = "3",
day = "1",
doi = "10.1002/jctb.5174",
language = "English (US)",
volume = "92",
pages = "455--462",
journal = "Journal of Chemical Technology and Biotechnology",
issn = "0268-2575",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine

AU - Wang, Nanxi

AU - Yuan, Zhe

AU - Niu, Wei

AU - Li, Qingsheng

AU - Guo, Jiantao

PY - 2017/3/1

Y1 - 2017/3/1

N2 - While the combined antiretroviral therapy has resulted in a significant decrease in HIV-1 related morbidity and mortality, the HIV-1 pandemic has not been substantially averted. To curtail the 2.4 million new infections each year, a prophylactic HIV-1 vaccine is urgently needed. This review first summarizes four major completed clinical efficacy trials of prophylactic HIV-1 vaccine and their outcomes. Next, it discusses several other approaches that have not yet advanced to clinical efficacy trials, but provided valuable insights into vaccine design. Among them, live-attenuated vaccines (LAVs) provided excellent protection in a non-human primate model. However, safety concerns have precluded the current version of LAVs from clinical application. As the major component of this review, two synthetic biology approaches for improving the safety of HIV-1 LAVs through controlling HIV-1 replication are discussed. Particular focus is on a novel approach that uses unnatural amino acid-mediated suppression of amber nonsense codon to generate conditionally replicating HIV-1 variants. The objective is to attract more attention towards this promising research field and to provoke creative designs and innovative utilization of the two control strategies.

AB - While the combined antiretroviral therapy has resulted in a significant decrease in HIV-1 related morbidity and mortality, the HIV-1 pandemic has not been substantially averted. To curtail the 2.4 million new infections each year, a prophylactic HIV-1 vaccine is urgently needed. This review first summarizes four major completed clinical efficacy trials of prophylactic HIV-1 vaccine and their outcomes. Next, it discusses several other approaches that have not yet advanced to clinical efficacy trials, but provided valuable insights into vaccine design. Among them, live-attenuated vaccines (LAVs) provided excellent protection in a non-human primate model. However, safety concerns have precluded the current version of LAVs from clinical application. As the major component of this review, two synthetic biology approaches for improving the safety of HIV-1 LAVs through controlling HIV-1 replication are discussed. Particular focus is on a novel approach that uses unnatural amino acid-mediated suppression of amber nonsense codon to generate conditionally replicating HIV-1 variants. The objective is to attract more attention towards this promising research field and to provoke creative designs and innovative utilization of the two control strategies.

KW - HIV-1 vaccine

KW - amber suppression

KW - live-attenuated vaccine

KW - unnatural amino acid

KW - virus engineering

UR - http://www.scopus.com/inward/record.url?scp=85011396920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011396920&partnerID=8YFLogxK

U2 - 10.1002/jctb.5174

DO - 10.1002/jctb.5174

M3 - Article

C2 - 28983143

AN - SCOPUS:85011396920

VL - 92

SP - 455

EP - 462

JO - Journal of Chemical Technology and Biotechnology

JF - Journal of Chemical Technology and Biotechnology

SN - 0268-2575

IS - 3

ER -